As PHLPP is lost in a majority of colon cancer patients26,29 and PHLPP loss renders cancer cells sensitive to glucose restriction-induced cell death, selectively targeting HK2 (such as using agents that dissociate HK2 from mitochondria) may provide a novel treatment option for colon cancer patients. The gene discussed is HK2; the disease is colonic neoplasm.